Cargando…
The differential immune response in mild versus fatal SARS-CoV2 infection()
This study compared the immune response in mild versus fatal SARS-CoV2 infection. Forty nasopharyngeal swabs with either productive mild infection (n = 20) or negative for SARS-CoV2 (n = 20) were tested along with ten lung sections from people who died of COVID-19 which contained abundant SARS-CoV2...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436872/ https://www.ncbi.nlm.nih.gov/pubmed/36113259 http://dx.doi.org/10.1016/j.anndiagpath.2022.152032 |
_version_ | 1784781470472077312 |
---|---|
author | Suster, David Tili, Esmerina Nuovo, Gerard J. |
author_facet | Suster, David Tili, Esmerina Nuovo, Gerard J. |
author_sort | Suster, David |
collection | PubMed |
description | This study compared the immune response in mild versus fatal SARS-CoV2 infection. Forty nasopharyngeal swabs with either productive mild infection (n = 20) or negative for SARS-CoV2 (n = 20) were tested along with ten lung sections from people who died of COVID-19 which contained abundant SARS-CoV2 and ten controls. There was a 25-fold increase in the CD3+T cell numbers in the viral positive nasopharyngeal swabs compared to the controls (p < 0.001) and no change in the CD3+T cell count in the fatal COVID-19 lungs versus the controls. CD11b + and CD206+ macrophage counts were significantly higher in the mild versus fatal disease (p = 0.002). In situ analysis for SARS-CoV2 RNA found ten COVID-19 lung sections that had no/rare detectable virus and also lacked the microangiopathy typical of the viral positive sections. These viral negative lung tissues when compared to the viral positive lung samples showed a highly significant increase in CD3+ and CD8 T cells (p < 0.001), equivalent numbers of CD163+ cells, and significantly less PDL1, CD11b and CD206+ cells (p = 0.002). It is concluded that mild SARS-CoV2 infection is marked by a much stronger CD3/CD8 T cell, CD11b, and CD206 macrophage response than the fatal lung disease where viral RNA is abundant. |
format | Online Article Text |
id | pubmed-9436872 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94368722022-09-02 The differential immune response in mild versus fatal SARS-CoV2 infection() Suster, David Tili, Esmerina Nuovo, Gerard J. Ann Diagn Pathol Original Contribution This study compared the immune response in mild versus fatal SARS-CoV2 infection. Forty nasopharyngeal swabs with either productive mild infection (n = 20) or negative for SARS-CoV2 (n = 20) were tested along with ten lung sections from people who died of COVID-19 which contained abundant SARS-CoV2 and ten controls. There was a 25-fold increase in the CD3+T cell numbers in the viral positive nasopharyngeal swabs compared to the controls (p < 0.001) and no change in the CD3+T cell count in the fatal COVID-19 lungs versus the controls. CD11b + and CD206+ macrophage counts were significantly higher in the mild versus fatal disease (p = 0.002). In situ analysis for SARS-CoV2 RNA found ten COVID-19 lung sections that had no/rare detectable virus and also lacked the microangiopathy typical of the viral positive sections. These viral negative lung tissues when compared to the viral positive lung samples showed a highly significant increase in CD3+ and CD8 T cells (p < 0.001), equivalent numbers of CD163+ cells, and significantly less PDL1, CD11b and CD206+ cells (p = 0.002). It is concluded that mild SARS-CoV2 infection is marked by a much stronger CD3/CD8 T cell, CD11b, and CD206 macrophage response than the fatal lung disease where viral RNA is abundant. Elsevier Inc. 2022-12 2022-09-02 /pmc/articles/PMC9436872/ /pubmed/36113259 http://dx.doi.org/10.1016/j.anndiagpath.2022.152032 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Contribution Suster, David Tili, Esmerina Nuovo, Gerard J. The differential immune response in mild versus fatal SARS-CoV2 infection() |
title | The differential immune response in mild versus fatal SARS-CoV2 infection() |
title_full | The differential immune response in mild versus fatal SARS-CoV2 infection() |
title_fullStr | The differential immune response in mild versus fatal SARS-CoV2 infection() |
title_full_unstemmed | The differential immune response in mild versus fatal SARS-CoV2 infection() |
title_short | The differential immune response in mild versus fatal SARS-CoV2 infection() |
title_sort | differential immune response in mild versus fatal sars-cov2 infection() |
topic | Original Contribution |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436872/ https://www.ncbi.nlm.nih.gov/pubmed/36113259 http://dx.doi.org/10.1016/j.anndiagpath.2022.152032 |
work_keys_str_mv | AT susterdavid thedifferentialimmuneresponseinmildversusfatalsarscov2infection AT tiliesmerina thedifferentialimmuneresponseinmildversusfatalsarscov2infection AT nuovogerardj thedifferentialimmuneresponseinmildversusfatalsarscov2infection AT susterdavid differentialimmuneresponseinmildversusfatalsarscov2infection AT tiliesmerina differentialimmuneresponseinmildversusfatalsarscov2infection AT nuovogerardj differentialimmuneresponseinmildversusfatalsarscov2infection |